These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22848251)

  • 1. Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients.
    Chen Q; Fei J; Wu L; Jiang Z; Wu Y; Zheng Y; Lu G
    Oncol Lett; 2011 Jul; 2(4):693-699. PubMed ID: 22848251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.
    Levicar N; Kos J; Blejec A; Golouh R; Vrhovec I; Frkovic-Grazio S; Lah TT
    Cancer Detect Prev; 2002; 26(1):42-9. PubMed ID: 12088202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
    Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
    Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
    Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
    Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
    Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients].
    Xiao W; Tong WL; Ma DD
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Nov; 29(11):723-6. PubMed ID: 17327049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of detection of cathepsin X and cystatin C in the sera of patients with lung cancer].
    Zhang X; Hou Y; Niu Z; Li W; Meng X; Zhang N; Yang S
    Zhongguo Fei Ai Za Zhi; 2013 Aug; 16(8):411-6. PubMed ID: 23945244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
    Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Urokinase plasminogen activator (u-PA) and urokinase type plasminogen activator receptor (u-PAR) in children with ulcerative colitis].
    Grabarczyk E; Szaflarska-Popławska A; Góralczyk K; Adamska I; Rość D
    Med Wieku Rozwoj; 2007; 11(1):41-4. PubMed ID: 17965463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
    Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
    Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
    Shiomi H; Eguchi Y; Tani T; Kodama M; Hattori T
    Am J Pathol; 2000 Feb; 156(2):567-75. PubMed ID: 10666386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
    Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
    Anticancer Res; 2000; 20(5C):3975-81. PubMed ID: 11268487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
    Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
    Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis.
    Guiducci S; Del Rosso A; Cinelli M; Perfetto F; Livi R; Rossi A; Gabrielli A; Giacomelli R; Iori N; Fibbi G; Del Rosso M; Cerinic MM
    Arthritis Res Ther; 2005; 7(6):R1244-53. PubMed ID: 16277677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy.
    Naumnik W; Niklińska W; Ossolińska M; Chyczewska E
    Folia Histochem Cytobiol; 2009; 47(2):207-13. PubMed ID: 19995705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
    Zheng MH; Fan Y; Panicker A; Smith A; Robertson T; Wysocki S; Robbins P; Papadimitriou JM; Wood DJ
    Am J Pathol; 1995 Dec; 147(6):1559-66. PubMed ID: 7495280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Int J Gynecol Cancer; 2000 Sep; 10(5):372-381. PubMed ID: 11240701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas.
    Lau HK; Kim M; Koo J; Chiu B; Murray D
    Clin Exp Metastasis; 1995 Nov; 13(6):492-8. PubMed ID: 7586807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens.
    Reuning U; Bang NU
    Arterioscler Thromb; 1992 Oct; 12(10):1161-70. PubMed ID: 1327097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas.
    Gondi CS; Lakka SS; Yanamandra N; Olivero WC; Dinh DH; Gujrati M; Tung CH; Weissleder R; Rao JS
    Cancer Res; 2004 Jun; 64(12):4069-77. PubMed ID: 15205313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.